Navigation Links
Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
Date:6/1/2011

in-class drugs, like NKP-1339, can take us one step further to address this high unmet need." While Dr. Burris commented, "The results to date indicate that NKP-1339 could be a promising new agent that would enhance our anti-cancer armamentarium."

About Niiki Pharma

Niiki Pharma Inc. is an oncology therapeutics development company with a pipeline of novel targeted anti-cancer agents. For more information, visit www.niikipharma.com.

About Translational Genomics Institute

The Translational Genomics Research Institute (TGen) is dedicated to conducting groundbreaking research with diseases such as cancer, neurological disorders and diabetes. For more information, visit www.tgen.org

About Sarah Canon Research Institute

Sarah Cannon Research Institute (SCRI) is a global clinical research organization focusing on advancing therapies and accelerating drug development in areas such as oncology, cardiology and gastroenterology. For more information, visit http://sarahcannonresearch.com.


'/>"/>
SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
3. Novel Device Shows Promise for Reducing HIV Among Men
4. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
5. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
6. International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter
7. MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
10. Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh
11. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Nanomix Inc., (Nanomix), a ... of mobile diagnostic tests to enable earlier ... pre-hospital settings, today announced it has received ... certification was awarded by the British Standards ... certification bodies. ISO 13485:2003 ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
(Date:11/26/2014)... SHENZHEN, China, Nov. 26, 2014 China Nepstar ... the "Company"), a leading retail drugstore chain in China ... announced its unaudited financial results for the third quarter ... ended September 30, 2014: , Same store sales increased ... , Revenue increased by 8.1% to RMB738.3 million (US$120.3 ...
Breaking Medicine Technology:Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11
... 2010 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, today announced its participation in ... Trade Fair with Congress, to be held November 17-20, ... well over 100 countries are expected to attend this ...
... Nov. 11, 2010 Dynatronics Corporation (Nasdaq: DYNT ) ... 2010. Sales for the quarter ended September 30, 2010 ... 2009. Net income for the quarter ended September 30, 2010, was ... share) for the same quarter in the prior fiscal year. ...
Cached Medicine Technology:Mindray Medical to Exhibit at MEDICA 2010 in Dusseldorf, Germany from November 17- 20, 2010 2Mindray Medical to Exhibit at MEDICA 2010 in Dusseldorf, Germany from November 17- 20, 2010 3Dynatronics Announces Fiscal First Quarter Results 2Dynatronics Announces Fiscal First Quarter Results 3
(Date:11/26/2014)... Senior Planning Services, providing “expert guidance for elder ... the adult demographic education and access to computer ... rough seas of applying for Medicaid. Part of this ... of Medicaid eligibility and proper planning, while also helping ... this coverage. , Senior Planning Services has made ...
(Date:11/26/2014)... IL (PRWEB) November 26, 2014 ... communication management solutions, has been award the ... Magazine. , This award comes as a great ... capabilities within the Lync ecosystem. Specifically, ISI offers ... all modes of Lync communication, including voice, video, ...
(Date:11/26/2014)... Albany, NY (PRWEB) November 26, 2014 ... industry research requirements or email the details on sales(at)researchmoz(dot)us ... "Worldwide diabetes and drug discovery market 2014" with deep ... Diabetes is the result of high blood sugar. The ... is directly linked to the growing number of diabetics ...
(Date:11/26/2014)... 2014 Bunion Bootie, the newest and ... an early celebration of the early holiday shopping season. ... at the promotional price of $29.95 each (normally $33.95 ... to any automatic discounts applied when buying more than ... for complete details. It’s simple: purchasing more Bunion ...
(Date:11/26/2014)... 2014 Louisiana Back Institute, leaders ... in minimally invasive spine surgery, announces today the ... rapidly growing provider network of orthopedic spine surgeons ... with the network’s continuing success providing the most ... residents who are suffering from orthopedic spine conditions ...
Breaking Medicine News(10 mins):Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
... The most poisonous substance on Earth already used medically ... wrinkles could be re-engineered for an expanded role in ... other diseases, scientists are reporting. Their study appears in ACS, ... that toxins, or poisons, produced by Clostridium botulinum ...
... HealthDay Reporter , TUESDAY, Nov. 29 (HealthDay ... hip replacement devices appear to work the same, a ... seem to be no more effective than older implants ... said. "Metal-on-metal and ceramic-on-ceramic hip implants might not ...
... Findings on coronary CT angiography (CTA), a noninvasive test to ... for men and women, according to a study presented today ... artery disease (CAD) is a narrowing of the blood vessels ... caused by a build-up of fat and other substances that ...
... TUESDAY, Nov. 29 (HealthDay News) -- Men are less willing ... have higher cancer death rates, a new study shows. ... New York City, Baltimore, and San Juan, Puerto Rico, who ... participants were aged 30 to 59, and 35 percent of ...
... Gass, MD, chief of surgery at Women & Infants Hospital ... Health Center in the hospital,s Program in Women,s Oncology, recently ... surgeon Krishna B. Clough, MD, medical director of the Paris ... novel surgical technique available to breast cancer patients through Women ...
... HOUSTON -- Combination treatment with everolimus, an inhibitor ... has shown to improve progression-free survival for patients ... carcinoid syndrome, according to researchers at The University ... of the international, randomized, placebo-controlled Phase III study ...
Cached Medicine News:Health News:New Hip Implants No Better Than Older Ones, Study Finds 2Health News:New Hip Implants No Better Than Older Ones, Study Finds 3Health News:Heart attack risk differs between men and women 2Health News:Men More Likely to Skip Cancer Screenings: Study 2Health News:Surgeon studies with world-renowned oncoplastic pioneer 2Health News:Surgeon studies with world-renowned oncoplastic pioneer 3Health News:Everolimus prolongs progression-free survival for patients with neuroendocrine tumors 2Health News:Everolimus prolongs progression-free survival for patients with neuroendocrine tumors 3
... Pulsavac Wound Debridement System ... for pulsatile irrigation,and debridement. ... range of fluid pressure ... lavage to a penetrating ...
... Amsco 3085 SP Surgical Table provides state-of-the-art ... now be networked with the HERMES Control ... Stryker Endoscopy) to allow the surgeon direct ... surgeon uses either simple voice commands or ...
... The ASC 2000 is ... care table, meeting good manufacturing ... regulatory requirements. It provides electro-hydraulic ... accessories for all ambulatory surgical ...
... The hands play an important part ... traumatic impairments and rheumatic changes can cause ... developing of the finger-joint prostheses was to ... reproduce the natural function as nearly possible.,The ...
Medicine Products: